Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Thomas Forst, Prof. Dr.
- Phone Number: +49 6131 576 36 16
- Email: thomasf@ikfe.de
Study Contact Backup
- Name: Swantje Anders
- Phone Number: +49 6131 327 90 22
- Email: s.anders@ikfe-cro.de
Study Locations
-
-
-
Mainz, Germany, 55116
- Recruiting
- IKFE GmbH
-
Contact:
- Swantje Anders
- Phone Number: +49 6131 327 90 22
- Email: s.anders@ikfe-cro.de
-
Contact:
- Thomas Forst, Prof., MD
- Phone Number: +49 6131 576 36 16
- Email: thomasf@ikfe.de
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diabetes mellitus type 2
HbA1c > 6.5%* ≤ 9.5%
* NOTE: Patients with cardiovascular preconditions (Coronary Heart Disease or Myocard Infarction) require an HbA1c > 7.0% ≤ 9.5%
- Treatment with Metformin at maximal or maximal tolerated dosage, stable for at least 3 months with indication for treatment with an additional medication as judged by the investigator
- Age 30 - 80 years
- Patient consents that his/her family physician will be informed of trial participation
Exclusion Criteria:
- Pre-treatment with insulin, peroxisome proliferator activated receptor (PPAR) gamma agonists or other oral antidiabetic treatments (except Metformin) within the last three months
- History of type-1-diabetes
- Fasting blood glucose >240mg/dl
- Uncontrolled hypertension (systolic blood pressure >160 and/or diastolic blood pressure >90)
- Anamnestic history of acute infections
- Anamnestic history of epilepsy
- Anamnestic history of hypersensitivity to the study drugs or to drugs with similar chemical structures
- History of severe or multiple allergies
- Hereditary galactose intolerance, lapp-lactase defect or glucose-galactose mal-absorption
- Treatment with any other investigational drug within 3 months before trial entry
- Pregnant or lactating women
- Sexually active woman of childbearing age not practicing a highly effective method of birth control as defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, hormonal intrauterine devices, sexual abstinence or vasectomized partner
- Progressive fatal disease
- History of drug or alcohol abuse in the past 2 years
- State after kidney transplantation
- Serum potassium > 5.5 mmol/L
- Acute myocardial infarction, open heart surgery or cerebral event (stroke/transient ischemic attack) within the previous 6 months
- Any elective surgery during study participation
- Have had more than one unexplained episode of severe hypoglycemia (defined as requiring assistance of another person due to disabling hypoglycemia) within 6 months prior to screening visit
- History of pancreatitis
- Anamnestic history of dehydration, diabetic precoma or diabetic ketoacidosis
- Acute or scheduled investigation with iodine containing radiopaque material
- Uncontrolled unstable angina pectoris
- Anamnestic history of pericarditis, myocarditis, endocarditis, hemodynamic relevant aortic stenosis, aortic aneurysm or heart insufficiency NYHA III or IV
- Anamnestic recent pulmonary embolism
- History of significant cardiovascular, respiratory, gastrointestinal, hepatic (ALAT and/or ASAT > 3 times the normal reference range), renal (GFR < 60 ml), neurological, psychiatric and/or hematological disease as judged by the investigator
- Lack of compliance or other similar reason that, according to investigator, precludes satisfactory participation in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Vildagliptin plus Metformin
Metformin (1000 mg BID) + Vildagliptin 50 mg twice daily
|
Vildagliptin 50 mg twice daily
Metformin 1000 mg BID
|
|
Active Comparator: Glimepirid plus Metformin
Metformin (1000 mg BID) + Glimepiride (individual dosage)
|
Metformin 1000 mg BID
Glimepiride at individual dose
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Postprandial increase in intact proinsulin levels in patient treated with Vildagliptin and Metformin compared to intact proinsulin levels in patients treated with Glimepiride and Metformin (Area under the curve 0-300 min)
Time Frame: One year
|
One year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Adverse events
Time Frame: One year
|
One year
|
|
Change in body weight
Time Frame: One year
|
One year
|
|
Fasting intact proinsulin levels
Time Frame: One year
|
One year
|
|
Max postprandial intact proinsulin levels
Time Frame: One year
|
One year
|
|
Retinal endothelial response to flicker light stimulation
Time Frame: One year
|
One year
|
|
Mean 24h systolic and diastolic blood pressure
Time Frame: One year
|
One year
|
|
Erythrocyte deformability
Time Frame: One year
|
One year
|
|
E-selectin
Time Frame: One year
|
One year
|
|
hsCRP
Time Frame: One year
|
One year
|
|
HbA1c
Time Frame: One year
|
One year
|
|
Fasting blood glucose
Time Frame: One year
|
One year
|
|
Number of hypoglycemic events
Time Frame: One year
|
One year
|
|
Drug related adverse events
Time Frame: One year
|
One year
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Thomas Forst, Prof. Dr., IKFE GmbH
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Enzyme Inhibitors
- Immunosuppressive Agents
- Immunologic Factors
- Protease Inhibitors
- Dipeptidyl-Peptidase IV Inhibitors
- Metformin
- Glimepiride
- Vildagliptin
Other Study ID Numbers
Other Study ID Numbers
- ikfe-Vilda-001
- 2011-004286-32 (EudraCT Number)
- CLAF237ADE06T (Other Identifier: Novartis Pharma GmbH)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.